Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related semaglutide-based drugs, Ozempic and Wegovy – since 2022 amid unprecedented ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...